Posts in category "Database"
Posts are organized into categories for ease of navigation:
- Algorithm - developments to the interpretation algorithm implemented in Python.
- Announcement - general news related to the Molecular Oncology Almanac.
- Database - changes and additions to the underlying knowledge base.
- Release - aggregated release notes from GitHub releases (serving as the project changelog).
-
Database release
This release contains updates to the current and draft versions of the database with FDA oncology approvals from June, July, and August 2025. The change log local to this repository has been removed and pointers now direct to news.moalmanac.org. Release notes will also continue to be available through this repository’s Releases.
Continue reading -
Database release
Updated current and draft version of the database with FDA oncology approvals from May and June, thus far, 2025.
Continue reading -
Database release
Updated current and draft version of the database with FDA oncology approvals from April 2025.
Continue reading -
Database release
In this release, we have normalized
Continue readingtherapy_namevalues to NCI thesaurus (#40) and merged an initial version of the next version of our database (#36), that aims to follow with GA4GH’s Genomic Knowledge Standards for the database schema (Read more here). -
Database release
Added entries:
- (FDA) ALK rearrangements and sensitivity to ensartinib for the treatment of adult patients with non-small cell lung cancer.
- (FDA) BRAF p.V600E and sensitivity to encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of patients with colorectal cancer.
- (FDA) KRAS p.G12C and sensitivity to panitumumab in combination with sotorasib for the treatment of adult patients with metastatic colorectal cancer.
-
Database release
This database release contains relevant FDA Oncology updates from March 2025.
Continue reading -
Database release
This release contains 1,001 approved relationships.
Continue reading -
Database release
This release contains 997 approved relationships.
Continue reading -
Database release
This release contains 993 approved relationships.
Continue reading -
Database release
This release contains 989 approved relationships.
Continue reading -
Database release
Added entries:
- (FDA) KRAS p.G12C and sensitivity to adagrasib in combination with cetuximab for patients with colorectal cancer received accelerated approval.
- (FDA) NTRK1/2/3 gene fusions and sensitivity to repotrectinib for patients with solid tumors received accelerated approval.
-
Database release
Added entries:
- (FDA) ALK fusions and sensitivity to alectinib for patients with non-small cell lung cancer.
- (FDA) BRAF p.V600E/K (p.V600 variants), rearrangements, and fusions and sensitivity to tovorafenib for patients with low-grade glioma.
- (FDA) EGFR p.L858R and exon 19 deletions and sensitivity to erlotinib for patients with non-small cell lung cancer.
- (FDA) EGFR p.L858R and exon 19 deletions and sensitivity to gefitinib for patients with non-small cell lung cancer.
-
Database release
Added entries:
- (FDA) ABL1 p.T315I and sensitivity to ponatinib for patients with acute lymphoid leukemia.
- (FDA) ABL1 p.T315I and sensitivity to ponatinib for patients with chronic myeloid leukemia.
- (FDA) BCR::ABL1 and sensitivity to ponatinib in combination with chemotherapy for patients with acute lymphoid leukemia.
- (FDA) BCR::ABL1 and sensitivity to ponatinib for patients with acute lymphoid leukemia.
-
Database release
Added entries:
- (FDA) ALK fusions and sensitivity to crizotinib for patients with anaplastic large cell lymphoma.
- (FDA) EGFR exon 20 insertions and sensitivity to amivantamab-vmjw in combination with carboplatin and pemetrexed for patients with non-small cell lung cancer.
- (FDA) EGFR exon 19 deletions or p.L858R and sensitivity to osimertinib in combination with cisplatin and pemetrexed for patients with locally advanced or metastatic non-small cell lung cancer.
- (FDA) EGFR exon 19 deletions or p.L858R and sensitivity to osimertinib for patients with metastatic non-small cell lung cancer.
- (FDA) MET exon 14 splice site and deletion variants (exon 14 skipping) and sensitivity to tepotinib for patients with metastatic non-small cell lung cancer.
-
Database release
Added entries:
- (FDA) BRAF p.V600E/K and sensitivity to vemurafenib for patients with Erdheim-Chester disease.
-
Database release
Added entries:
- (FDA) ERBB2 amplification and sensitivity to neratinib in combination with capecitabine for patients with breast cancer.
-
Database release
Added entries:
- (FDA) PIK3CA and AKT somatic variants and PTEN loss of function variants and sensitivity to capivasertib in combination with fulvestrant for patients with breast cancer.
- (FDA) ROS1 rearrangements and sensitivity to repotrectinib in patients with nsclc.
-
Database release
This month’s data release features recent FDA approvals, updates of mutational signatures from version 2 to 3.4, updates to the source fields for several citations, removal of several entries, revising format of all clinical guideline citations, and the
Continue readingpublication_datefield has been populated for all current database records. -
Database release
Added entries:
- (Preclinical) ATM copy number deletions and sensitivity to talazoparib in osteosarcoma.
- (Preclinical) BAP1 copy number deletions and sensitivity to talazoparib in osteosarcoma.
- (Preclinical) BARD1 copy number deletions and sensitivity to talazoparib in osteosarcoma.
- (Preclinical) CCNE1 copy number amplifications and sensitivity to dinaciclib in osteosarcoma.
- (Preclinical) CDK4 copy number amplifications and sensitivity to palbociclib in osteosarcoma.
- (Preclinical) CHEK2 copy number deletions and sensitivity to talazoparib in osteosarcoma.
- (Preclinical) FANCA copy number deletions and sensitivity to talazoparib in osteosarcoma.
- (Preclinical) FGFR1 copy number amplifications and sensitivity to AZ4547 and PD173074 in osteosarcoma.
- (Preclinical) MYC copy number amplifications and sensitivity to AT7519 in osteosarcoma.
- (Preclinical) PTEN copy number deletions and sensitivity to MK-2206 and rapamycin in osteosarcoma.
- (Preclinical) RB1 somatic variants and sensitivity to olaparib and palbociclib in osteosarcoma.
- (Preclinical) TP53 copy number deletions and sensitivity to talazoparib in osteosarcoma.
- (Preclinical) TP53 somatic variants and sensitivity to NSC59984 in osteosarcoma.
-
Database release
Added entries:
- (FDA) BRCA1 somatic and germline variants and sensitivity to abiraterone acetate in combination with niraparib for patients with metastatic castration-resistant prostate cancer.
- (FDA) BRCA2 somatic and germline variants and sensitivity to abiraterone acetate in combination with niraparib for patients with metastatic castration-resistant prostate cancer.
- (FDA) MSI-H and sensitivity to dostarlimab-gxly in combination with carboplatin and paclitaxel, followed by single agent dostarlimab-gxly, in endometrial cancer.
-
Database release
Added entries:
- (FDA) BRCA1 and BRCA2 somatic and germline variants and sensitivity to olaparib in combination with abiraterone and prednisone or prednisolone for patients with metastatic castration-resistant prostate cancer.
- (FDA) BRCA1 and BRCA2 germline variants and sensitivity to olaparib for patients with metastatic pancreatic adenocarcinoma.
- (FDA) BRCA1 and BRCA2 germline variants and sensitivity to olaparib for the treatment of adult patients with HER2-negative high risk early breast cancer.
- (FDA) ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, and RAD51C somatic variants and sensitivity to talazoparib in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer.
-
Database release
Added entries:
- (FDA) BRAF p.V600E and sensitivity to dabrafenib in combination with trametinib for pediatric patients with low-grade glioma.
-
Database release
In this release, we add two recent precision oncology approvals from the FDA regarding ER signaling inhibition in two cancer types.
Continue reading -
Database release
In this release, we add two recent precision oncology approvals from the FDA.
Continue reading -
Database release
In this release, we have removed neoantigen burden as a cataloged feature type and combined Silencing with Knockdown feature types. We additionally expanded upon fields required for each feature type within our S.O.P.
Continue reading -
Database release
Added entries:
- (FDA) FGFR2 rearrangements and sensitivity to futibatinib in intrahepatic cholangiocarcinoma.
-
Database release
Added entries:
- (FDA) FGFR1 rearrangements and sensitivity to pemigatinib in myeloid/lymphoid neoplasms.
-
Database release
Added entries:
- (FDA) ALK-EML4 and sensitivity to crizotinib in inflammatory myofibroblastic tumors.
- (Clinical trial) BRCA1 and BRCA2 germline variants and sensitivity to olaparib.
- (Clinical evidence) BRCA2 copy number deletion and loss-of-function somatic variants and sensitivity to olaparib in uterine leiomyosarcoma.
- (Clinical evidence) CDKN2A deletion and sensitivity to palbociclib in uterine leiomyosarcoma.
- (Clinical evidence) MYOCD amplification as a diagnostic for strong smooth muscle differentiation in leiomyosarcoma.
- (Preclinical) RB1 copy number deletion and somatic variants and sensitivity to olaparib and talazoparib in prostate cancer.
- (Preclinical) RB1 knockout and resistance to palbociclib in prostate cancer.
- (Preclinical) USP11 silencing and sensitivity to olaparib in osteosarcoma.
- (Inferential) ATRX copy number deletions and poor prognosis in leiomyosarcoma.
- (Inferential) BRCA1 and BRCA2 copy number deletion and loss-of-function somatic variants and sensitivity to PARP inhibition (KU0058684, KU0058948).
- (Inferential) CDKN2C deletion may confer sensitivity to CDK4/6 inhibitors.
- (Inferential) MAP2K4 and MAPK7 copy number amplification and not sensitive to chemotherapy as well as poor prognosis in osteosarcoma.
- (Inferential) PDGFRA copy number amplification and poor prognosis in breast cancer.
- (Inferential) PTEN copy number deletion and poor prognosis in uterine leiomyosarcoma.
- (Inferential) PTEN copy number deletion and sensitivity to sapanisertib in combination with alpelisib in uterine leiomyosarcoma.
-
Database release
Revised entries:
- (FDA) KRAS p.G12C and sensitivity to sotorasib’s description was revised to remove underscores.
- (Preclinical) KRAS somatic variants and sensitivity to FGFR1 inhibitor + trametinib was revised to remove a trailing space from the therapy name.
-
Database release
Revised entries:
- (FDA) KRAS p.G12C and sensitivity to sotorasib’s description was revised to remove underscores.
- (Preclinical) KRAS somatic variants and sensitivity to FGFR1 inhibitor + trametinib was revised to remove a trailing space from the therapy name.
-
Database release
Added entries:
- (FDA) BCR-ABL1 and sensitivity to asciminib in chronic phase chronic myeloid leukemia.
- (Clinical evidence) SPOP missense somatic variants and favorable prognosis in de-novo metastatic castration-sensitive prostate cancer.
- (Clinical evidence) SPOP missense somatic variants and sensitivity to abiraterone in metastatic castration-resistant prostate cancer
- (Clinical evidence) SPOP missense somatic variants and sensitivity to anti-androgen therapy.
- (Inferential) CD274 amplification and sensitivity to atezolizumab in non-small cell lung cancer.
-
Database release
Added entries:
- (FDA) EGFR exon 20 insertion variants and sensitivity to mobocertinib in non-small cell lung cancer.
-
Database release
The following assertions sourced from recent FDA approvals were added to the Molecular Oncology Almanac in this release -
Continue reading -
Database release
The following recent FDA approvals were added to the Molecular Oncology Almanac in this release -
Continue reading -
Database release
The following changes were made to the Molecular Oncology Almanac in this release -
Continue reading -
Database release
In addition to the content changes listed below, this release added a therapeutic strategy (
Continue readingtherapy_strategy) for all sensitive and resistance relationships. -
Database release
Added entries:
- (FDA) RET somatic variants associated with sensitivity to pralsetinib in advanced or metastatic medullary thyroid cancer.
- (FDA) RET fusions associated with sensitivity to pralsetinib in advanced or metastatic thyroid cancer.
- (Inferential) CDK274 amplifications associated with sensitivity to chemotherapy in combination with pembrolizumab in locally recurrent or metastatic triple-negative breast cancer.
-
Database release
This release focuses on FDA approvals since March 2020. In addition to the following changes, the citation style for all FDA approved associated have been updated to match American Medical Association (AMA) style formatting.
Continue reading